Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371823 · ClinicalTrials.gov registry record · Phase 4
Vascular Dysfunction in Hypertensive Postmenopausal Women
A Phase 4 study, sponsored by University of Delaware.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT03371823 is a Phase 4 study that was terminated before completion, run by University of Delaware. The registered enrollment target is 8 participants.
The verdict
NCT03371823, a Phase 4 study, was terminated before completion, sponsored by University of Delaware.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the role of ET-1 in mediating vasoconstrictor tone in hypertensive postmenopausal women (PMW) alone and in combination with a commonly prescribed Angiotensin II (ANG II) antagonist. The long term goal is to understand the mechanisms contributing to hypertension (HTN) in PMW. This study is the first step in reaching our goal.
Interventions
- OTHER Normotensive
- DRUG Hypertensives
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03371823
The ClinicalTrials.gov registry entry for NCT03371823 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Delaware, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normotensive is the first listed.
NCT03371823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03371823 about?
NCT03371823 is a clinical study titled "Vascular Dysfunction in Hypertensive Postmenopausal Women". The purpose of this study is to investigate the role of ET-1 in mediating vasoconstrictor tone in hypertensive postmenopausal women (PMW) alone and in combination with a commonly prescribed Angiotensin II (ANG II) antagonist. The long term goal is to understand the mechanisms contributing to hyperte...
What is the current status of trial NCT03371823?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2017-09-01. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03371823?
The interventions under investigation include: Normotensive (OTHER), Hypertensives (DRUG).
Who is sponsoring clinical trial NCT03371823?
This trial is sponsored by University of Delaware, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.